利伐沙班联合阿司匹林与单用阿司匹林在既往经皮冠状动脉介入治疗患者中的比较(COMPASS-PCI)
COMPASS试验预设亚组分析,纳入16 560例慢性冠脉综合征患者,其中9 862例(59.6%)有既往PCI史,随机接受利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次或单用阿司匹林100 mg每日一次。无论有无既往PCI,双通路抑制均一致降低MACE和死亡率,但增加大出血;在既往PCI患者中,无论距上次PCI时间(早至1年、远至10年)或既往心肌梗死史,MACE降低均一致。
要点
- 既往PCI的慢性冠脉综合征患者中,双通路抑制较单用阿司匹林降低MACE(4.0% vs 5.5%,HR 0.74)。
- 双通路抑制降低死亡率(2.5% vs 3.5%,HR 0.73),但增加大出血(3.3% vs 2.0%,HR 1.72)。
- 距上次PCI 1年及以上者,MACE和死亡获益与距PCI时间无关。
核心结论
- 在既往PCI的慢性冠脉综合征患者中,利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次较单用阿司匹林100 mg每日一次一致降低MACE和死亡率,但增加大出血。
- 在既往PCI 1年及以上患者中,MACE和死亡获益与距上次PCI时间无关。
研究设计与样本
- COMPASS试验预设亚组分析,纳入27 395例中16 560例慢性冠脉综合征患者随机分配至双通路抑制或单用阿司匹林,其中9 862例(59.6%)有既往PCI。
- 既往PCI患者平均年龄68.2±7.8岁,女性19.4%,糖尿病35.7%,既往心肌梗死74.8%,多支PCI 38.0%。
- 距PCI至随机化平均5.4年(SD 4.4),随访1.98年(SD 0.72)。
主要发现
- 既往PCI患者中,双通路抑制组MACE发生率4.0% vs 阿司匹林组5.5%(HR 0.74,95%CI 0.61-0.88);无PCI者4.4% vs 5.7%(HR 0.76,95%CI 0.61-0.94),P-interaction=0.85。
- 既往PCI患者中,双通路抑制组死亡率2.5% vs 3.5%(HR 0.73,95%CI 0.58-0.92);无PCI者4.1% vs 5.0%(HR 0.80,95%CI 0.64-1.00),P-interaction=0.59。
- 既往PCI患者中,双通路抑制组大出血发生率3.3% vs 2.0%(HR 1.72,95%CI 1.34-2.21);无PCI者2.9% vs 1.8%(HR 1.58,95%CI 1.15-2.17),P-interaction=0.68。
- 既往PCI患者中,无论距上次PCI时间(早至1年、远至10年,P-interaction=0.65)或既往心肌梗死史(P-interaction=0.64),双通路抑制较阿司匹林降低MACE均一致。
临床怎么用
- 对既往PCI 1年及以上的慢性冠脉综合征患者,可考虑利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次以降低MACE和死亡风险,但需权衡大出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COMPASS trial (Cardiovascular Outcomes for People using Anticoagulation Strategies) demonstrated that dual pathway inhibition (DPI) with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily versus aspirin 100 mg once daily reduced the primary major adverse cardiovascular event (MACE) outcome of cardiovascular death, myocardial infarction, or stroke, as well as, mortality, in patients with chronic coronary syndromes or peripheral arterial disease. Whether this remains true in patients with a history of percutaneous coronary intervention (PCI) is unknown. METHODS: In a prespecified subgroup analysis from COMPASS, we examined the outcomes of patients with chronic coronary syndrome with or without a previous PCI treated with DPI versus aspirin alone. Among patients with a previous PCI, we studied the effects of treatment according to the timing of the previous PCI. RESULTS: Of the 27 395 patients in COMPASS, 16 560 patients with a chronic coronary syndrome were randomly assigned to DPI or aspirin, and, of these, 9862 (59.6%) had previous PCI (mean age 68.2±7.8, female 19.4%, diabetes mellitus 35.7%, previous myocardial infarction 74.8%, multivessel PCI 38.0%). Average time from PCI to randomization was 5.4 years (SD, 4.4) and follow-up was 1.98 (SD, 0.72) years. Regardless of previous PCI, DPI versus aspirin produced consistent reductions in MACE (PCI: 4.0% versus 5.5%; hazard ratio [HR], 0.74 [95% CI, 0.61-0.88]; no PCI: 4.4% versus 5.7%; HR, 0.76 [95% CI, 0.61-0.94], P-interaction=0.85) and mortality (PCI: 2.5% versus 3.5%; HR, 0.73 [95% CI, 0.58-0.92]; no PCI: 4.1% versus 5.0%; HR, 0.80 [95% CI, 0.64-1.00], P-interaction=0.59), but increased major bleeding (PCI: 3.3% versus 2.0%; HR, 1.72 [95% CI, 1.34-2.21]; no PCI: 2.9% versus 1.8%; HR, 1.58 [95% CI, 1.15-2.17], P-interaction=0.68). In those with previous PCI, DPI compared with aspirin produced consistent (robust) reductions in MACE irrespective of time since previous PCI (as early as 1 year and as far as 10 years; P-interaction=0.65), irrespective of having a previous myocardial infarction (P-interaction=0.64). CONCLUSIONS: DPI compared with aspirin produced consistent reductions in MACE and mortality but with increased major bleeding with or without previous PCI. Among those with previous PCI 1 year and beyond, the effects on MACE and mortality were consistent irrespective of time since last PCI. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01776424.
引用
- Bainey KR, Welsh RC, Connolly SJ, et al. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation. 2020. PMID: 32178526. doi:10.1161/CIRCULATIONAHA.119.044598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。